Â鶹ŮÓÅ

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • Â鶹ŮÓÅ Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

TRENDING TOPICS:

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Mar 30 2015

Full Issue

Breakthrough Hep C Drugs Spike Medicare Costs By $4.5 Billion

Consumers also face the high cost of prescription drugs. Many will turn to discount programs that claim big savings, but some pharmacists tell buyers to beware.

Medicare spent $4.5 billion last year on new, pricey medications that cure the liver disease hepatitis C — more than 15 times what it spent the year before on older treatments for the disease, previously undisclosed federal data shows. The extraordinary outlays for these breakthrough drugs, which can cost $1,000 a day or more, will be borne largely by federal taxpayers, who pay for most of Medicare’s prescription drug program. But the expenditures will also mean higher deductibles and maximum out-of-pocket costs for many of the program’s 39 million seniors and disabled enrollees, who pay a smaller share of its cost, experts and federal officials said. (Ornstein, 3/29)

Many consumers are looking for a quick-fix to the high-cost of prescription drugs. But can you really expect all that much from paper discount cards that pop up in the mail? "Save up to 75 percent on your prescriptions instantly," reads the back of the free card from American Prescription Discounts. Really? Well, make sure you understand the small print and recognize that we're not talking about 75 percent off your co-pay. (Tompor, 3/27)

Meanwhile, the Food and Drug Administration is taking a light touch in overseeing health care monitoring devices like the Apple Watch -

With Apple Inc. and fellow Silicon Valley companies edging further into health care, the U.S. agency in charge of oversight says it will give the technology industry leeway to develop new products without aggressive regulation. Bakul Patel, who oversees the new wave of consumer-focused health products at the Food and Drug Administration, said most wearable gadgets such as the soon-to-be-released Apple Watch and health-focused applications for smartphones have a way to go before warranting close scrutiny from the agency. (Satariano, 3/30)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 Â鶹ŮÓÅ